Levi & Korsinsky is investigating potential claims on behalf of purchasers of BioSante Pharmaceuticals, Inc. (“BioSante” or the “Company”) (Nasdaq: BPAX) securities concerning possible violations of federal securities laws.

For more information, click here: http://zlk.9nl.com/biosante-pharmaceuticals-bpax.

The investigation stems from allegations that BioSante issued materially false and misleading statements designed to artificially inflate the Company’s stock price. In particular, the investigation concerns allegations that senior officials at BioSante misled investors about the commercial viability and effectiveness of LibiGel, an experimental compound intended to boost women’s libido. On December 14, 2011, the Company disclosed that its product LibiGel failed to yield positive results in efficacy tests. Upon this news, shares of BioSante stock plummeted from a trading high of $2.65 on December 14, 2011 to a close of $0.48 on December 15, 2011.

If you own BioSante stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/biosante-pharmaceuticals-bpax.html.

Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010